Evangelia Kokalaki, PhD
London, England, United Kingdom
837 followers
500+ connections
London, England, United Kingdom
837 followers
500+ connections
About
I am a highly motivated individual who enjoys working in a fast paced, stimulating and…
Activity
-
BREAKING: A few months after Summit Therapeutics, Inc. shocked the oncology world with an early claim that its lung cancer drug ivonescimab had…
BREAKING: A few months after Summit Therapeutics, Inc. shocked the oncology world with an early claim that its lung cancer drug ivonescimab had…
Liked by Evangelia Kokalaki, PhD
-
Our Head of Quality Control Rebecca Moore will be speaking at the 3rd Annual Cell Therapy Analytical Development Summit in London. Rebecca’s…
Our Head of Quality Control Rebecca Moore will be speaking at the 3rd Annual Cell Therapy Analytical Development Summit in London. Rebecca’s…
Liked by Evangelia Kokalaki, PhD
-
Legend Biotech’s CAR-T #Carvykti Approved for R/R MM Indication in China August 28, 2024 - CGTLive The NMPA’s decision was made with reference to…
Legend Biotech’s CAR-T #Carvykti Approved for R/R MM Indication in China August 28, 2024 - CGTLive The NMPA’s decision was made with reference to…
Liked by Evangelia Kokalaki, PhD
Experience
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Publications
-
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
Molecular Therapy
This is a publication on how we generated a high sensitivity CAR against CD22, in order to combine with the CD19 targeting product, CAT.
Other authors -
Patents
More activity by Evangelia
-
I am so glad to see the moving into the lung cancer trials in the global trials #CancerVaccine World-first lung cancer vaccine trials launched…
I am so glad to see the moving into the lung cancer trials in the global trials #CancerVaccine World-first lung cancer vaccine trials launched…
Liked by Evangelia Kokalaki, PhD
-
Organoids just got an immune upgrade! In our new paper, just published in Nature Magazine, we equipped intestinal organoids with an autologous…
Organoids just got an immune upgrade! In our new paper, just published in Nature Magazine, we equipped intestinal organoids with an autologous…
Liked by Evangelia Kokalaki, PhD
-
Autolus is delighted to announce some recent promotions that recognize each individuals significant leadership experience. Andrea Braun-Scherhag…
Autolus is delighted to announce some recent promotions that recognize each individuals significant leadership experience. Andrea Braun-Scherhag…
Liked by Evangelia Kokalaki, PhD
-
New Strategy for Preventing Relapse After CAR T-Cell Therapy Booster treatment improved long-term immune therapy success in models of multiple…
New Strategy for Preventing Relapse After CAR T-Cell Therapy Booster treatment improved long-term immune therapy success in models of multiple…
Liked by Evangelia Kokalaki, PhD
-
A Platform to Deliver Single and Bi-specific Cas9/guide RNA to Perturb Genes in Vitro and in Vivo Although CRISPR/Cas9 technology is poised to…
A Platform to Deliver Single and Bi-specific Cas9/guide RNA to Perturb Genes in Vitro and in Vivo Although CRISPR/Cas9 technology is poised to…
Liked by Evangelia Kokalaki, PhD
-
I’m super excited to share this discovery! The plastic-eating fungus is HERE! OK - Here’s the deal: Earlier this month, scientists reportedly found…
I’m super excited to share this discovery! The plastic-eating fungus is HERE! OK - Here’s the deal: Earlier this month, scientists reportedly found…
Liked by Evangelia Kokalaki, PhD
-
Amazing platform! It integrates T cell receptor and cytokine signals in a T-cell immunological synapse! Generating a therapeutic index for IL-2!
Amazing platform! It integrates T cell receptor and cytokine signals in a T-cell immunological synapse! Generating a therapeutic index for IL-2!
Liked by Evangelia Kokalaki, PhD
-
An exciting development in the field: CAR-T Meets CAR-E, an Enhancer Platform to Prevent Cancer Relapse All too often, CAR-T cells beat back cancer…
An exciting development in the field: CAR-T Meets CAR-E, an Enhancer Platform to Prevent Cancer Relapse All too often, CAR-T cells beat back cancer…
Liked by Evangelia Kokalaki, PhD
-
We are thrilled to share that the FDA has cleared our Investigational New Drug (IND) application for UB-VV111, an in-situ generated CAR T-cell…
We are thrilled to share that the FDA has cleared our Investigational New Drug (IND) application for UB-VV111, an in-situ generated CAR T-cell…
Liked by Evangelia Kokalaki, PhD
-
University of Pennsylvania will spin out Jim Wilson’s gene therapy program and split it into two companies Jim Wilson will leave the university when…
University of Pennsylvania will spin out Jim Wilson’s gene therapy program and split it into two companies Jim Wilson will leave the university when…
Liked by Evangelia Kokalaki, PhD
-
Let's Talk Quality: The Podcast🎙️is back for Season Two this month! Here's a sneak peak from my conversation with Markus Gruell, SVP Quality at…
Let's Talk Quality: The Podcast🎙️is back for Season Two this month! Here's a sneak peak from my conversation with Markus Gruell, SVP Quality at…
Liked by Evangelia Kokalaki, PhD
-
#BreakingNews We’ve received U.S. FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer…
#BreakingNews We’ve received U.S. FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer…
Liked by Evangelia Kokalaki, PhD
-
Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk Viking Therapeutics (VKTX) stock rocketed Thursday after the…
Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk Viking Therapeutics (VKTX) stock rocketed Thursday after the…
Liked by Evangelia Kokalaki, PhD
-
In vivo CAR-T progress and perspectives: if we can provide proof-of-concept that in vivo CAR-T works equivalent to conventional CAR-T, it will be the…
In vivo CAR-T progress and perspectives: if we can provide proof-of-concept that in vivo CAR-T works equivalent to conventional CAR-T, it will be the…
Liked by Evangelia Kokalaki, PhD
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More